Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 555 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Adult, Solid Tumor Cancer
Interventions
DF6215, pembrolizumab, KEYTRUDA®
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 5 more
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Technetium Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cytoreductive Nephrectomy, Active Comparator
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
387
States / cities
Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more
Conditions
Kidney Cancer
Interventions
aldesleukin, bevacizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 8 more
Conditions
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
Interventions
Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neulasta
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
92
States / cities
Los Angeles, California • Aurora, Colorado • Aurora, Illinois + 56 more
Conditions
Kidney Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Sunitinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
37
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 28 more
Conditions
Metastatic Renal Cell Carcinoma, Brain Metastases
Interventions
Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
Drug · Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV, Non Small Cell Lung Cancer, NSCLC, Gastrointestinal Cancer, Gastrointestinal Squamous Cell Cancer, Gastrointestinal Adenocarcinoma, Pancreatic Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Metastatic Solid Tumor
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Kidney Cancer
Interventions
aldesleukin, sargramostim, vinblastine sulfate
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Nivolumab, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Conditions
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
Interventions
Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
396
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more
Conditions
Renal Cell Carcinoma
Interventions
CTT1057
Drug
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Interventions
JANX008
Drug
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Duarte, California • Sacramento, California • San Diego, California + 15 more
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions
AZD6750, rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Conditions
Renal Cell Carcinoma
Interventions
MB-002
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Orange, California • Buffalo, New York • Chapel Hill, North Carolina
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 12 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
558
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
Conditions
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
198
States / cities
Gilbert, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 157 more
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Axitinib, Cabozantinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Springdale, Arkansas • Louisville, Kentucky • St Louis, Missouri + 5 more
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
47
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more